Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Obinutuzumab β in CIDP
NCT07696377Phase 2Not yet recruiting
- Start
- Jul 2026
- Primary completion
- Jan 2030
01
Overview
A Phase 2 trial of obinutuzumab in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Planned start Jul 2026; status: not yet recruiting.
02
Drugs
obinutuzumab
03
Conditions
chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
Beyond the preview
Go deeper on NCT07696377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07696377.